Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

NCT03382977 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

70

Enrollment

INDUSTRY

Sponsor class

Stopped VBI Bankruptcy

Conditions

Glioblastoma Multiforme

Interventions

BIOLOGICAL: VBI-1901
DRUG: Carmustine
DRUG: Lomustine

Sponsor

VBI Vaccines Inc.